Revive Therapeutics Announces Positive Results of its Novel Cannabinoid Delivery Technology

Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) has announced positive initial results from its research product with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.

As quoted in the press release:

The research project evaluated tannin-chitosan (TNN-CHT) based hydrogel formulations in combination with synthetic cannabidiol (CBD) in an anti-inflammatory preclinical model. Initial results successfully demonstrated a stable formulation of the TNN-CHT composites and synthetic CBD (TNN-CHT/CBD). The TNN-CHT/CBD formulation shown to attenuate LPS-induced macrophage activation in a dose-response manner, showing a reduction for inducible nitric oxide synthase (iNOS), as well as an increase on intracellular production of tumor necrosis factor alpha (TNF-a) as the concentration of CBD is increased. In summary, the TNN-CHT/CBD formulation exhibits anti-inflammatory properties and suggested that the TNN-CHT composites have anti-inflammatory activity that may complement CBD. The project is ongoing with further optimization of the TNN-CHT/CBD formulation and final results will be made available before the end of the year.

“This is a significant development milestone as we have successfully demonstrated that the delivery technology in combination with cannabidiol is able to effectively reduce inflammation offering a novel and potentially effective therapeutic option for a broad range of indications that would benefit from cannabinoid therapies,” said Dr. Jess D. Reed, Professor of Animal Nutrition at the University of Wisconsin-Madison. “We are optimizing the formulation for permeation and inflammatory studies in order to further validate the potential of the cannabinoid delivery technology.”

“I am pleased with these initial results as it has successfully demonstrated that the cannabinoid delivery technology has shown a positive effect in reducing inflammation and has the potential to be a unique cannabinoid delivery technology offering novel solutions for the medical cannabis and pharmaceutical sectors,” said Craig Leon, Chief Executive Officer of Revive.

Click here to read the full press release.

Biotech Stocks in 2018

Find out how the market will look this year

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Biotech Stocks in 2018

Find out how the market will look this year


Leave a Reply